

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/829,040	04/09/2001	Junying Yuan	00742/057002	8382
21559	7590 03/24/2004	EXAMINER		INER
CLARK & ELBING LLP 101 FEDERAL STREET			WANG, SHENGIUN	
BOSTON, MA 02110			ART UNIT	PAPER NUMBER
			1617	
			DATE MAILED: 03/24/2004	•

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/829,040	YUAN ET AL.
Office Action Summary	Examiner	Art Unit
	Shengjun Wang	1617
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet wi	
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a relif NO period for reply is specified above, the maximum statutory perice. - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may a recept within the statutory minimum of thirty od will apply and will expire SIX (6) MON the cause the application to become A.	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication.
Status		
1) Responsive to communication(s) filed on 15 2a) This action is FINAL . 2b) Th 3) Since this application is in condition for allow closed in accordance with the practice under	nis action is non-final. vance except for formal matte	ers, prosecution as to the merits is
Disposition of Claims	·	, -
4) Claim(s) 1-16 and 18-24 is/are pending in the 4a) Of the above claim(s) 4,5,10,11,13,16 is/ 5) Claim(s) is/are allowed. 6) Claim(s) 1-3,6-9,12,14,15 and 18-24 is/are re 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/	are withdrawn from consider	ration.
Application Papers		
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The path or declaration is objected to by the E	ccepted or b) objected to be drawing(s) be held in abeyand ction is required if the drawing(s	ce. See 37 CFR 1.85(a).
11) The oath or declaration is objected to by the E	.xammer. Note the attached	Office Action or form PTO-152.
Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureat * See the attached detailed Office action for a list	nts have been received. nts have been received in Apportity documents have been reau (PCT Rule 17.2(a)).	plication No eceived in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/I	mmary (PTO-413) Mail Date ormal Patent Application (PTO-152)

Application/Control Number: 09/829,040

Art Unit: 1617

DETAILED ACTION

Receipt of applicants' amendments and remarks submitted December 15, 2003 is acknowledged.

1. Initially, it is noted that applicants' remarks that claim 11 does not read on elected species is correct. Therefore, claims 10 and 16-17 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, claim 4, 5, 11 and 13 are withdrawn from further consideration as drawn to nonelected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 9.

The claims have been examined insofar as they're read on the elected invention and species.

Claim Rejections 35 U.S.C. 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. Claims 1-3, 6-9, 12, 14, 15 and 18-24 rejected under 35 U.S.C. 103(a) as being unpatentable over Klunk et al. (US 6,417,178), in view of Klunk et al. and Huang et al. for reasons set forth in the prior office action.

Response to the Arguments

Applicants' amendments and remarks submitted December 15, 2003 have been fully considered, but are not persuasive for reasons discussed below.

Application/Control Number: 09/829,040 Page 3

Art Unit: 1617

- 4. In response to applicant's argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, the suggestion, or motivation are found both in the prior art, and in the knowledge generally available to one of ordinary skill in the art. Particularly, cited prior arts teaches that Congo red and the Congo red analogues employed in '178 are known to be similarly useful as amyloid binding agents for reducing toxicity, one of ordinary skill in the art would have seen the employment of Congo red for the utility disclosed in '178.
- 5. Applicants allege that Klunk references teach away from the instant invention because Klunk discloses that it is known Congo red is inferior to Chrysamine G in term of entering blood-brain barrier. For example, Klunk 2 states "Since Congo red is too highly charged to enter the brain in *significant quantities*,..." Congo red, which may not be as efficient as Chrysamine G in term for entering brain, is nevertheless useful an amyloid binding agents, and is able to enter brain. Disclosed examples and preferred embodiments do not constitute a teaching away from a broader disclosure or no preferred embodiments. In re Susi, 440 F.2d 442, 169 USPQ 423 (CCPA 1971). "A known or obvious composition does not become patentable simply because *it has been described as somewhat inferior to some other product for the same use.*" In re Gurley, 27 F.3d 551, 554, 31 USPQ2d 1130, 1132 (Fed. Cir. 1994) (The invention was directed to an epoxy impregnated fiber-reinforced printed circuit material. The applied prior art

Application/Control Number: 09/829,040

Art Unit: 1617

reference taught a printed circuit material similar to that of the claims but impregnated with polyester-imide resin instead of epoxy. The reference, however, disclosed that epoxy was known for this use, but that epoxy impregnated circuit boards have "relatively acceptable dimensional stability" and "some degree of flexibility," but are inferior to circuit boards impregnated with polyester-imide resins. The court upheld the rejection concluding that applicant's argument that the reference teaches away from using epoxy was insufficient to overcome the rejection since "Gurley asserted no discovery beyond what was known in the art." 27 F.3d at 554, 31 USPQ2d at 1132.). Further, applicants have not provided evidence to the contrary for Congo red's ability to enter blood brain barrier.

With respect to the remarks about Huang references, note Huang was cited to show two facts: Congo red binding to the amyloid from Huntington diseases; and amyloid from Huntington disease has expanded polyglutamine segment. Nowhere in the detailed disclose negate those facts. Note the obvious rejections is based on the totality of the cited references, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

Applicants also contend that the instant invention is directed to the treatment of expanded polyglutamine repeats and not $A\beta$ diseases. The arguments are not persuasive. Particularly, expanded polyglutamine repeats would read on $A\beta$ diseases. See, particularly, claims 13 and 14 herein and Huang references.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time 6. policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang, Ph.D. whose telephone number is (571)272-0632. The examiner can normally be reached on Monday-Friday from 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571)272-0629. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9302.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

SHENGJUN WANG
PRIMARY EXAMINED

Shengjun Wang

March 13, 2004